Mahamaya Lifesciences Ltd
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]
- Market Cap ₹ 391 Cr.
- Current Price ₹ 167
- High / Low ₹ 205 / 111
- Stock P/E 23.4
- Book Value ₹ 52.4
- Dividend Yield 0.00 %
- ROCE 20.0 %
- ROE 19.4 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE SME IPO
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 137 | 162 | 266 | 329 | |
| 128 | 148 | 241 | 295 | |
| Operating Profit | 9 | 13 | 25 | 34 |
| OPM % | 7% | 8% | 9% | 10% |
| 0 | 1 | 1 | 1 | |
| Interest | 3 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 2 | 2 |
| Profit before tax | 5 | 8 | 17 | 24 |
| Tax % | 28% | 27% | 26% | 31% |
| 4 | 5 | 13 | 17 | |
| EPS in Rs | 2.72 | 3.99 | 7.22 | 7.14 |
| Dividend Payout % | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 34% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 65% |
| TTM: | 30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 24% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 18 | 23 |
| Reserves | 18 | 24 | 32 | 99 |
| 24 | 55 | 58 | 91 | |
| 34 | 33 | 81 | 98 | |
| Total Liabilities | 78 | 112 | 189 | 311 |
| 21 | 21 | 27 | 35 | |
| CWIP | 2 | 3 | 4 | 8 |
| Investments | 0 | 0 | 0 | 0 |
| 55 | 88 | 158 | 268 | |
| Total Assets | 78 | 112 | 189 | 311 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 1 | -23 | -0 | -30 | |
| -3 | -2 | -7 | -16 | |
| 3 | 24 | 9 | 81 | |
| Net Cash Flow | 1 | -1 | 1 | 35 |
| Free Cash Flow | -2 | -25 | -5 | -38 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 22% | -159% | 6% | -75% |
Ratios
Standalone / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 25 | 64 | 67 | 78 |
| Inventory Days | 109 | 137 | 167 | 194 |
| Days Payable | 90 | 61 | 92 | 88 |
| Cash Conversion Cycle | 45 | 140 | 142 | 184 |
| Working Capital Days | 14 | 15 | 30 | 49 |
| ROCE % | 21% | 26% | 20% |
Documents
Announcements
-
Publication Of Executive Interview In Agropages Magazine (2026 India Focus Issue)
- Executive interview published in AgroPages 2026 India Focus Issue on October 9, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
-
Announcement under Regulation 30 (LODR)-Change in Management
- Mahamaya Lifesciences approved multiple board changes, including new chairman and managing director from Nov 1, 2026.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 24th AGM voting results declared; 9 resolutions passed on September 29, 2026.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- 24th AGM held on September 29, 2026; resolutions included auditor adoption, director reappointment, and management redesignations.
Business Profile[1]
The company manufactures pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations (MNCs). It imports scientifically researched molecules, secures registrations with the Central Insecticides Board, and develops these molecules into technical-grade and value-added formulations, which are marketed to domestic manufacturers and global MNCs.